|Bid||2.54 x 0|
|Ask||2.58 x 0|
|Day's range||2.5400 - 2.5800|
|52-week range||2.5200 - 2.8300|
|Beta (3Y monthly)||0.59|
|PE ratio (TTM)||9.85|
|Forward dividend & yield||0.10 (3.91%)|
|1y target est||3.20|
SINGAPORE, Nov 8, 2018 - (ACN Newswire) - Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) ("SeD"), through its subsidiary, Global BioLife Inc. ("Global BioLife") is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International Society for Neuroscience (SfN) in San Diego, California. SeD said the presentation titled, "Myricetin derivatives ameliorate deficits in 6-OHDA animal model of Parkinson's disease," will detail the results of an Integrated Drug Discovery program at Charles River Discovery Service covering Pharmacokinetics, Maximum Toxicity Dose, and an in vivo animal model of Parkinson's Disease.
In this article, I will take a look at Hong Leong Finance Limited’s (SGX:S41) most recent earnings update (31 March 2018) and compare these latest figures against its performance overRead More...
SGX 40V) wishes to provide shareholders an update on the Group's operations. SGX Catalist-listed SeD (Stock Code: 40V) has strategically positioned itself as an investment holding company and embarked into new ventures whilst keeping on track with its existing businesses. The Group is involved in incubation of companies and the development of innovative and disruptive technologies and its business has undergone transformation to enable the Group to compete in the new economy so as to generate benefits for its shareholders.
Leading Hong Leong Finance Limited (SGX:S41) as the CEO, Leng Kwek took the company to a valuation of S$1.21B. Understanding how CEOs are incentivised to run and grow their companyRead More...
SINGAPORE, May 31, 2018 - (ACN Newswire) - Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. ("Global BioLife"), has developed a low glycemic index, naturally modified sugar - Laetose - which has the potential to affect the world's sugar market. Global BioLife has established a joint venture, Sweet Sense, Inc. ("Sweet Sense"), with Quality Ingredients, LLC. ("Quality Ingredients"), to refine the invention and to create a scalable manufacturing process.